Locations
Waltham, MA, USA · Arlington, MA, USA
industry
Pharmaceuticals
Size
51-200 employees
Stage
IPO
founded in
2009
Weaving along Hawaii's Na Pali Coast is the famous, breathtaking Kalalau Trail. This trail is not only notable for its strenuous path and terrain that is difficult to traverse, but also known for its unsurpassed beauty. Kalalau was early inspiration for us, today representing our innovative spirit and deep commitment to advancing the treatment of eye diseases. Kala Bio is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe diseases of the eye. Kala Bio’s biologics-based investigational therapies utilize Kala Bio’s proprietary Mesenchymal Stem Cell Secretome (MSC-S) platform. Kala Bio’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases.
Something looks off?